Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Holding AVDL?
Track your performance easily
AVDL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.50 - $19.09
Previous Close$13.65
Volume156.77K
Average Volume (3M)1.30M
Market Cap
$1.32B
Enterprise Value$1.21B
Total Cash (Recent Filing)$105.11M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 06, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding96,270,528
10 Day Avg. Volume1,013,603
30 Day Avg. Volume1,304,452
Standard Deviation0.25
R-Squared0.10
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)18.70
Price to Sales (P/S)13.99
Price to Cash Flow (P/CF)-18.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue43.33
Enterprise Value/Gross Profit44.68
Enterprise Value/Ebitda-8.28
Forecast
1Y Price Target
$25.00Price Target Upside82.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Avadel Pharmaceuticals News
PremiumCompany Announcements
Avadel Pharmaceuticals Advances Pediatric Narcolepsy Treatment Review
Bulls Say, Bears Say
Bulls Say
Legal VictoryAvadel Pharmaceuticals won a patent dispute against Jazz Pharmaceuticals, allowing the launch of Lumryz for daytime sleepiness in narcolepsy to proceed uninterrupted.
Market Share PotentialAnalyst continues to believe that Lumryz can grab more than 20% of the market share in narcolepsy.
Sales PerformanceLumryz sales of $41.5M in the quarter were above consensus of $37.5M and our estimate of $39.1M.
Bears Say
Financial PerformanceThe stock is off some in a good tape probably because the inventory bump (helped sales by ~$2.5M) drove the sales upside.
Legal ChallengesInvestor anxiety about ongoing litigation involving competitor Jazz is holding the stock back.
Regulatory IssuesThe court granted a request preventing Avadel from seeking FDA approval for Lumryz in idiopathic hypersomnia until Jazz's patent expires in 2036.
---
Ownership Overview
14.57% Insiders
9.55% Mutual Funds
43.58% Other Institutional Investors
32.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $9.50 and its highest was $19.09 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Currently, no data Available
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.179 by $0.039.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is -$0.07.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 96,270,530 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.179. Following the earnings report the stock price went down -2.236%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Among the largest hedge funds holding Avadel Pharmaceuticals’s share is Woodline Partners LP. It holds Avadel Pharmaceuticals’s shares valued at 21M.
---
Avadel Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (82.62% Upside)
$25.00 (82.62% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 7.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.18%
12-Months-Change
Fundamentals
Return on Equity
-99.52%
Trailing 12-Months
Asset Growth
-21.62%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.
---
AVDL Company Deck
---
AVDL Earnings Call
Q2 2024
0:00 / 0:00
---
AVDL Stock 12 Month Forecast
Average Price Target
$25.00
▲(82.62% Upside)
Technical Analysis
Best Analysts Covering AVDL
1 Year
1 Year Success Rate
17/24 ratings generated profit
1 Year Average Return
+66.72%
reiterated a buy rating 5 months ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +66.72% per trade.
---